U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H10ClN5O2
Molecular Weight 267.672
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CENOBAMATE

SMILES

c1ccc(c(c1)[C@]([H])(Cn2ncnn2)OC(=N)O)Cl

InChI

InChIKey=GFHAXPJGXSQLPT-VIFPVBQESA-N
InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1

HIDE SMILES / InChI

Molecular Formula C10H10ClN5O2
Molecular Weight 267.672
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Cenobamate (also known as YKP3089) is a small molecule sodium channel blocker in development for the treatment of partial-onset seizures in adult patients. In mice and rats, Cenobamate displayed an anticonvulsant activity in the maximal electroshock test and prevented seizures induced by chemical convulsants such as pentylenetetrazol and picrotoxin. In addition, Cenobamate was reported to be effective in two models of focal seizure, the hippocampal kindled rat and the mouse 6 Hz psychomotor seizure models. Two completed adequate and well-controlled clinical studies demonstrated a significant reduction in focal seizures with Cenobamate in patients with epilepsy, and a long-term open-label phase 3 safety clinical trial is currently ongoing. Cenobamate is considered a new generation antiepileptic therapy and clinical trials have shown that it may be more effective and safer than existing drugs. If licensed, Cenobamate will offer a new adjunctive treatment option for patients with partial focal epilepsy.

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
24.1 μg/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CENOBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
46.1 μg/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CENOBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
17.2 μg/mL
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CENOBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4.42 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CENOBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.1 μg/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CENOBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
484 μg × h/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CENOBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
873 μg × h/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CENOBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1960 μg × h/mL
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CENOBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
322 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CENOBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4.53 μg × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CENOBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
482 μg × h/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CENOBAMATE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
861 μg × h/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CENOBAMATE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
75.6 h
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CENOBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
54.7 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CENOBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
35.9 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CENOBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
40%
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CENOBAMATE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
40%
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CENOBAMATE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Disc. AE: Tachycardia, Gastroesophageal reflux disease...
Other AEs: Somnolence, Dizziness...
AEs leading to
discontinuation/dose reduction:
Tachycardia
Gastroesophageal reflux disease
Drug hypersensitivity
Nystagmus
Aggression
Depression
Dyspnea
Other AEs:
Somnolence (grade 1-2, 22.1%)
Dizziness (grade 1-2, 22.1%)
Headache (grade 1-2, 12.4%)
Nausea (grade 1-2, 11.5%)
Fatigue (grade 1-2, 10.6%)
Nystagmus (grade 1-2, 9.7%)
Balance disorder (grade 1-2, 8%)
Urinary tract infection (grade 1-2, 8%)
Upper respiratory tract infection (grade 1-2, 7.1%)
Tremor (grade 1-2, 6.2%)
Nasopharyngitis (grade 1-2, 6.2%)
Constipation (grade 1-2, 5.3%)
Diarrhea (grade 1-2, 5.3%)
Vomiting (grade 1-2, 5.3%)
Anxiety (grade 1-2, 0.9%)
Sources:
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Other AEs: Vertigo, Diplopia...
Other AEs:
Vertigo (1%)
Diplopia (6%)
Vision blurred (2%)
Nausea (6%)
Constipation (2%)
Diarrhea (1%)
Vomiting (2%)
Dry mouth (1%)
Abdominal pain (2%)
Dyspepsia (2%)
Nasopharyngitis (2%)
Pharyngitis (1%)
Urinary tract infection (2%)
Head injury (1%)
Alanine aminotransferase increased (1%)
Aspartate aminotransferase increased (1%)
Weight decreased (2%)
Decreased appetite (3%)
Back pain (4%)
Musculoskeletal chest pain (2%)
Somnolence (19%)
Dizziness (18%)
Fatigue (12%)
Headache (10%)
Balance disorder (3%)
Gait disturbance (1%)
Dysarthria (2%)
Nystagmus (3%)
Ataxia (2%)
Aphasia (2%)
Dysgeusia (2%)
Memory impairment (2%)
Sedation (1%)
Confusional state (2%)
Irritability (1%)
Suicidal ideation (2%)
Dysmenorrhea (1%)
Pruritus (2%)
Rash papular (2%)
ALT increased (0.9%)
Sources:
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 109
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 109
Sources:
Other AEs: ALT increased...
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Other AEs: Vertigo, Diplopia...
Other AEs:
Vertigo (1%)
Diplopia (7%)
Vision blurred (2%)
Nausea (6%)
Constipation (4%)
Diarrhea (3%)
Vomiting (4%)
Dry mouth (1%)
Abdominal pain (2%)
Dyspepsia (2%)
Nasopharyngitis (4%)
Pharyngitis (2%)
Urinary tract infection (5%)
Alanine aminotransferase increased (1%)
Aspartate aminotransferase increased (1%)
Decreased appetite (1%)
Back pain (2%)
Musculoskeletal chest pain (1%)
Somnolence (22%)
Dizziness (22%)
Fatigue (14%)
Headache (12%)
Balance disorder (5%)
Gait disturbance (3%)
Dysarthria (1%)
Nystagmus (7%)
Ataxia (3%)
Aphasia (1%)
Memory impairment (1%)
Sedation (1%)
Confusional state (2%)
Suicidal ideation (1%)
Dysmenorrhea (2%)
Pruritus (1%)
Asthenia (1%)
Tremor (3%)
Pollakiuria (1%)
Hiccups (1%)
Dyspnea (3%)
Sources:
350 mg 1 times / day steady, oral (mean)
Recommended
Dose: 350 mg, 1 times / day
Route: oral
Route: steady
Dose: 350 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 442
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 442
Sources:
Disc. AE: Ataxia, Dizziness...
AEs leading to
discontinuation/dose reduction:
Ataxia (>1)
Dizziness (>1)
Somnolence (>1)
Diplopia (>1)
Nystagmus (>1)
Vertigo (>1)
Cognitive deterioration (0.4%)
Sources:
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Other AEs: Nystagmus, Ataxia...
Other AEs:
Nystagmus (6%)
Ataxia (6%)
Aphasia (4%)
Asthenia (3%)
Vertigo (6%)
Diplopia (15%)
Palpitations (2%)
Vision blurred (4%)
Nausea (9%)
Constipation (8%)
Diarrhea (5%)
Vomiting (5%)
Dry mouth (3%)
Abdominal pain (1%)
Nasopharyngitis (5%)
Head injury (2%)
Alanine aminotransferase increased (4%)
Aspartate aminotransferase increased (3%)
Weight decreased (1%)
Decreased appetite (5%)
Back pain (5%)
Somnolence (37%)
Dizziness (33%)
Fatigue (24%)
Headache (10%)
Balance disorder (9%)
Gait disturbance (8%)
Dysarthria (7%)
Dysgeusia (2%)
Memory impairment (2%)
Migraine (2%)
Sedation (2%)
Tremor (1%)
Confusional state (3%)
Euphoric mood (2%)
Irritability (2%)
Dysmenorrhea (1%)
Hiccups (1%)
ALT increased (2.7%)
Sources:
750 mg 1 times / day single, oral
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: single
Dose: 750 mg, 1 times / day
Sources:
healthy
n = 7
Other AEs: Nervous system disorders...
AEs

AEs

AESignificanceDosePopulation
Aggression Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Depression Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Drug hypersensitivity Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Dyspnea Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Gastroesophageal reflux disease Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Nystagmus Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Tachycardia Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Anxiety grade 1-2, 0.9%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Fatigue grade 1-2, 10.6%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Nausea grade 1-2, 11.5%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Headache grade 1-2, 12.4%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Dizziness grade 1-2, 22.1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Somnolence grade 1-2, 22.1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Constipation grade 1-2, 5.3%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Diarrhea grade 1-2, 5.3%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Vomiting grade 1-2, 5.3%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Nasopharyngitis grade 1-2, 6.2%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Tremor grade 1-2, 6.2%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Upper respiratory tract infection grade 1-2, 7.1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Balance disorder grade 1-2, 8%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Urinary tract infection grade 1-2, 8%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
Nystagmus grade 1-2, 9.7%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18 to 65 years
n = 113
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: 18 to 65 years
Sex: M+F
Population Size: 113
Sources:
ALT increased 0.9%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Alanine aminotransferase increased 1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Aspartate aminotransferase increased 1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Diarrhea 1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Dry mouth 1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Dysmenorrhea 1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Gait disturbance 1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Head injury 1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Irritability 1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Pharyngitis 1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Sedation 1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Vertigo 1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Headache 10%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Fatigue 12%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Dizziness 18%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Somnolence 19%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Abdominal pain 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Aphasia 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Ataxia 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Confusional state 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Constipation 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Dysarthria 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Dysgeusia 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Dyspepsia 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Memory impairment 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Musculoskeletal chest pain 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Nasopharyngitis 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Pruritus 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Rash papular 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Suicidal ideation 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Urinary tract infection 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Vision blurred 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Vomiting 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Weight decreased 2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Balance disorder 3%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Decreased appetite 3%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Nystagmus 3%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Back pain 4%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Diplopia 6%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
Nausea 6%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 108
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 108
Sources:
ALT increased 1.8%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 109
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 109
Sources:
Alanine aminotransferase increased 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Aphasia 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Aspartate aminotransferase increased 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Asthenia 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Decreased appetite 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Dry mouth 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Dysarthria 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Hiccups 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Memory impairment 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Musculoskeletal chest pain 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Pollakiuria 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Pruritus 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Sedation 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Suicidal ideation 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Vertigo 1%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Headache 12%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Fatigue 14%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Abdominal pain 2%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Back pain 2%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Confusional state 2%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Dysmenorrhea 2%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Dyspepsia 2%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Pharyngitis 2%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Vision blurred 2%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Dizziness 22%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Somnolence 22%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Ataxia 3%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Diarrhea 3%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Dyspnea 3%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Gait disturbance 3%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Tremor 3%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Constipation 4%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Nasopharyngitis 4%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Vomiting 4%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Balance disorder 5%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Urinary tract infection 5%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Nausea 6%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Diplopia 7%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Nystagmus 7%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 223
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 223
Sources:
Cognitive deterioration 0.4%
Disc. AE
350 mg 1 times / day steady, oral (mean)
Recommended
Dose: 350 mg, 1 times / day
Route: oral
Route: steady
Dose: 350 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 442
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 442
Sources:
Ataxia >1
Disc. AE
350 mg 1 times / day steady, oral (mean)
Recommended
Dose: 350 mg, 1 times / day
Route: oral
Route: steady
Dose: 350 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 442
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 442
Sources:
Diplopia >1
Disc. AE
350 mg 1 times / day steady, oral (mean)
Recommended
Dose: 350 mg, 1 times / day
Route: oral
Route: steady
Dose: 350 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 442
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 442
Sources:
Dizziness >1
Disc. AE
350 mg 1 times / day steady, oral (mean)
Recommended
Dose: 350 mg, 1 times / day
Route: oral
Route: steady
Dose: 350 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 442
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 442
Sources:
Nystagmus >1
Disc. AE
350 mg 1 times / day steady, oral (mean)
Recommended
Dose: 350 mg, 1 times / day
Route: oral
Route: steady
Dose: 350 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 442
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 442
Sources:
Somnolence >1
Disc. AE
350 mg 1 times / day steady, oral (mean)
Recommended
Dose: 350 mg, 1 times / day
Route: oral
Route: steady
Dose: 350 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 442
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 442
Sources:
Vertigo >1
Disc. AE
350 mg 1 times / day steady, oral (mean)
Recommended
Dose: 350 mg, 1 times / day
Route: oral
Route: steady
Dose: 350 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 442
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 442
Sources:
Abdominal pain 1%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Dysmenorrhea 1%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Hiccups 1%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Tremor 1%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Weight decreased 1%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Headache 10%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Diplopia 15%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Dysgeusia 2%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Euphoric mood 2%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Head injury 2%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Irritability 2%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Memory impairment 2%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Migraine 2%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Palpitations 2%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Sedation 2%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
ALT increased 2.7%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Fatigue 24%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Aspartate aminotransferase increased 3%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Asthenia 3%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Confusional state 3%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Dry mouth 3%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Dizziness 33%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Somnolence 37%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Alanine aminotransferase increased 4%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Aphasia 4%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Vision blurred 4%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Back pain 5%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Decreased appetite 5%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Diarrhea 5%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Nasopharyngitis 5%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Vomiting 5%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Ataxia 6%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Nystagmus 6%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Vertigo 6%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Dysarthria 7%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Constipation 8%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Gait disturbance 8%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Balance disorder 9%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Nausea 9%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, mean age 39 years
n = 111
Health Status: unhealthy
Condition: partial-onset seizures
Age Group: mean age 39 years
Sex: M+F
Population Size: 111
Sources:
Nervous system disorders 71.4%
750 mg 1 times / day single, oral
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: single
Dose: 750 mg, 1 times / day
Sources:
healthy
n = 7
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
yes [IC50 170 uM]
yes (co-administration study)
Comment: Cenobamate increases exposure of phenytoin, omeprazole (CYP2C19 probe substrate) by approximately 2-fold when administered concomitantly
Page: 11.0
yes [IC50 280 uM]
yes [IC50 720 uM]
yes
yes
yes
yes (co-administration study)
Comment: Cendobamate decreases midazolam concentration upto 4-fold (CYP3A induction) when administered concomitantly.
Page: 11.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Antiepileptic Drugs in Clinical Development: Differentiate or Die?
2017
Patents

Sample Use Guides

target dose of 200 mg/day
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Jun 26 12:51:07 UTC 2021
Edited
by admin
on Sat Jun 26 12:51:07 UTC 2021
Record UNII
P85X70RZWS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CENOBAMATE
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
2H-TETRAZOLE-2-ETHANOL, .ALPHA.-(2-CHLOROPHENYL)-, CARBAMATE (ESTER), (.ALPHA.R)-
Systematic Name English
YKP-3089
Code English
CARBAMIC ACID (R)-(+)-1-(2-CHLOROPHENYL)-2-(2H-TETRAZOL-2-YL)ETHYL ESTER
Systematic Name English
CENOBAMATE [INN]
Common Name English
XCOPRI
Brand Name English
2H-TETRAZOLE-2-ETHANOL, .ALPHA.-(2-CHLOROPHENYL)-, 2-CARBAMATE, (.ALPHA.R)-
Systematic Name English
2H-TETRAZOLE-2-ETHANOL, ALPHA-(2-CHLOROPHENYL)-, YL)ETHYL)CARBAMATE CARBAMATE (ESTER), (.ALPHA.R)-
Systematic Name English
CENOBAMATE [WHO-DD]
Common Name English
CENOBAMATE [USAN]
Common Name English
(1R)-1-(2-CHLOROPHENYL)-2-(TETRAZOL-YL)ETHYL)CARBAMATE
Common Name English
YKP3089
Code English
(1R)-1-(2-CHLOROPHENYL)-2-(2H-TETRAZOL-2-YL)ETHYL CARBAMATE
Systematic Name English
Classification Tree Code System Code
DEA NO. 2720
Created by admin on Sat Jun 26 12:51:08 UTC 2021 , Edited by admin on Sat Jun 26 12:51:08 UTC 2021
Code System Code Type Description
CAS
913088-80-9
Created by admin on Sat Jun 26 12:51:08 UTC 2021 , Edited by admin on Sat Jun 26 12:51:08 UTC 2021
PRIMARY
NCI_THESAURUS
C174837
Created by admin on Sat Jun 26 12:51:08 UTC 2021 , Edited by admin on Sat Jun 26 12:51:08 UTC 2021
PRIMARY
FDA UNII
P85X70RZWS
Created by admin on Sat Jun 26 12:51:08 UTC 2021 , Edited by admin on Sat Jun 26 12:51:08 UTC 2021
PRIMARY
DRUG CENTRAL
5355
Created by admin on Sat Jun 26 12:51:08 UTC 2021 , Edited by admin on Sat Jun 26 12:51:08 UTC 2021
PRIMARY
DRUG BANK
DB06119
Created by admin on Sat Jun 26 12:51:08 UTC 2021 , Edited by admin on Sat Jun 26 12:51:08 UTC 2021
PRIMARY
PUBCHEM
11962412
Created by admin on Sat Jun 26 12:51:08 UTC 2021 , Edited by admin on Sat Jun 26 12:51:08 UTC 2021
PRIMARY
INN
10116
Created by admin on Sat Jun 26 12:51:08 UTC 2021 , Edited by admin on Sat Jun 26 12:51:08 UTC 2021
PRIMARY
LACTMED
Cenobamate
Created by admin on Sat Jun 26 12:51:08 UTC 2021 , Edited by admin on Sat Jun 26 12:51:08 UTC 2021
PRIMARY
RXCUI
2265690
Created by admin on Sat Jun 26 12:51:08 UTC 2021 , Edited by admin on Sat Jun 26 12:51:08 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TRANSPORTER -> INHIBITOR
WEAK
METABOLIC ENZYME -> INDUCER
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
WEAK
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INDUCER
BINDER->LIGAND
Cenobamate mainly binds with human albumin protein and not with ?1-acid glycoprotein.
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC SINGLE- OR MULTIPLE-DOSE ADMINISTRATION

FASTED STATE

blood to plasma ratio PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC